1mg, best e pharmacy in India

Ranibizumab

INFORMATION

Uses

Ranibizumab is used in the treatment of wet form of age-related macular degeneration (growth of abnormal blood vessels in eye leading to gradual loss of vision), diabetic macular edema (accumulation of fluid in eye of diabetic patients) and macular oedema due to retinal vein occlusion.

How it works

Ranibizumab injection belongs to a class of medications called vascular endothelial growth factor (VEGF) antagonists. Ranibizumab binds extracellular VEGF thereby stopping abnormal blood vessel growth and leakage in the eye(s) which may lead to vision loss in people with wet AMD.

Common side effects

Allergic reaction, Shortness of breath, Altered vision, Bleeding around the eye, Chest pain, Eye itching, Dry eye, Eye pain, Increased sensitivity to light, Eye swelling, Eyelid swelling, Foreign body sensation in eyes, Dizziness, Headache, Nausea, Increased intraocular pressure, Eye redness, Slow speech, Difficult speech, Teary eyes, Visual floater, Weakness, Numbness of extremity

AVAILABLE MEDICINE

Expert advice

  • Patients should not drive or use machines immediately after receiving ranibizumab intravitreal injection which may influence the driving ability or ability to operate machines.
  • Consult your ophthalmologist immediately if the eye becomes red, sensitive to light, painful or develops a change in vision.
  • Before taking ranibizumab, inform you doctor if you are pregnant, planning a pregnancy or breast-feeding.

Frequently asked questions

Ranibizumab

Q.Is ranibizumab FDA approved?
Yes, ranibizumab is approved by the FDA

Q.What is ranibizumab injection and how does it work?
Ranibizumab injection belongs to a class of medications called vascular endothelial growth factor (VEGF) antagonists. Ranibizumab is used for the treatment of conditions that affect vision such as exudative (wet) neovascular age-related macular degeneration (AMD), macular edema (swelling) following retinal vein occlusion and macular edema (swelling) due to diabetes. Ranibizumab binds extracellular VEGF thereby stopping abnormal blood vessel growth and leakage in the eye(s) which may lead to vision loss in people with wet AMD.


Content on this page was last updated on 21 November, 2016, by Dr. Varun Gupta (MD Pharmacology)